Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.40 |
| ▸ | CHRNG | P07510 | 2/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.40 |
| ▸ | CHRND | Q07001 | 2/20 | 0.40 |
| ▸ | CD40 | P25942 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25877836 | 0.88 | QRFPR (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25877088 | 0.86 | AKT1 (0.47) | — | |
| SCHEMBL25976319 | 0.84 | OPRM1 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25976646 | 0.84 | OPRM1 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25877985 | 0.84 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL25757530 | 0.84 | CTSB (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25873942 | 0.83 | CHRNB2 (0.52) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL25757406 | 0.79 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL25874061 | 0.79 | EPHX2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL25496961 | 0.79 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | CHRNB2 4676/4885CHRNB4 4429/4885CHRNA3 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.